What is he best known for?
The fields of study he is best known for:
Leukemia, Cancer research, Myeloid leukemia, Molecular biology and Immunology are his primary areas of study.
Bjørn Tore Gjertsen interconnects Myeloid and Toxicity in the investigation of issues within Leukemia.
His Cancer research study integrates concerns from other disciplines, such as Mutation, Breast cancer, Gene expression and Chemokine receptor.
Bjørn Tore Gjertsen has included themes like Regulation of gene expression, Fms-Like Tyrosine Kinase 3 and Pharmacology in his Myeloid leukemia study.
His research integrates issues of Cancer cell, Cell and Autocrine signalling in his study of Regulation of gene expression.
His Immunology research includes themes of Internal medicine, Angiogenesis and Haematopoiesis.
His most cited work include:
- Single Cell Profiling of Potentiated Phospho-Protein Networks in Cancer Cells (623 citations)
- Single Cell Profiling of Potentiated Phospho-Protein Networks in Cancer Cells (623 citations)
- Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. (411 citations)
What are the main themes of his work throughout his whole career to date?
His scientific interests lie mostly in Cancer research, Myeloid leukemia, Leukemia, Internal medicine and Immunology.
His study in Cancer research is interdisciplinary in nature, drawing from both Cell culture, Apoptosis, Signal transduction, Stem cell and Bone marrow.
His work in Myeloid leukemia addresses issues such as Pharmacology, which are connected to fields such as Targeted therapy.
In his work, Bioinformatics and Regulation of gene expression is strongly intertwined with Myeloid, which is a subfield of Leukemia.
His Internal medicine research integrates issues from Gastroenterology and Oncology.
The study incorporates disciplines such as Progenitor cell, Disease and Chemotherapy in addition to Immunology.
He most often published in these fields:
- Cancer research (57.04%)
- Myeloid leukemia (48.15%)
- Leukemia (39.51%)
What were the highlights of his more recent work (between 2018-2021)?
- Cancer research (57.04%)
- Myeloid leukemia (48.15%)
- Internal medicine (32.35%)
In recent papers he was focusing on the following fields of study:
Bjørn Tore Gjertsen mainly investigates Cancer research, Myeloid leukemia, Internal medicine, Oncology and Cell culture.
His Cancer research research incorporates themes from Tyrosine kinase, Ovarian cancer, Stem cell, Programmed cell death and In vivo.
His Myeloid leukemia research is multidisciplinary, incorporating perspectives in Apoptosis, Leukemia, Retinoic acid and Bone marrow.
His Leukemia study frequently involves adjacent topics like Myeloid.
His Oncology research is multidisciplinary, incorporating elements of Cancer, Chemotherapy regimen, Mutation, Immune system and Cohort.
The concepts of his Cell culture study are interwoven with issues in Cell, Methylation, Bortezomib and Gene isoform.
Between 2018 and 2021, his most popular works were:
- Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia (27 citations)
- Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival. (10 citations)
- Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival. (10 citations)
In his most recent research, the most cited papers focused on:
His primary scientific interests are in Cancer research, Myeloid leukemia, Internal medicine, Oncology and Leukemia.
His Cancer research research is multidisciplinary, relying on both Cell culture, Cell, Methylation, In vivo and Immunotherapy.
His In vivo research incorporates elements of Cancer cell and Protein kinase B.
The Myeloid leukemia study combines topics in areas such as Apoptosis, Lipid metabolism, Retinoic acid and Fatty acid metabolism.
His work deals with themes such as Progressive disease, Progression-free survival, Lactate dehydrogenase, Bevacizumab and Metastatic malignant melanoma, which intersect with Oncology.
His work carried out in the field of Leukemia brings together such families of science as Myeloid, Gastroenterology, Adverse effect, Philadelphia chromosome and Bone marrow.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
